⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289451 | 0.78 | SLC6A3 (0.41) | — | |
| SCHEMBL11040005 | 0.76 | SLC6A2 (0.30) | — | |
| SCHEMBL25206694 | 0.70 | — | — | |
| SCHEMBL25267230 | 0.70 | — | — | |
| SCHEMBL17925907 | 0.67 | — | — | |
| SCHEMBL6651767 | 0.67 | MAP3K14 (0.43) | — | |
| SCHEMBL3697943 | 0.63 | — | — | |
| SCHEMBL31650636 | 0.63 | — | — | |
| SCHEMBL12621045 | 0.63 | — | — | |
| SCHEMBL29229739 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751934-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORP (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5688990-A | FORMING CHEMICAL INTERMEDIATES FOR AZETIDINONE COMPOUNDS THAT INHIBIT CHOLESTEROL BIOSYNTHESIS FOR PREVENTION OF ATHEROSCLEROSIS | SHANKAR BANDARPALLE B (US) | 1997-11-18 | — | — | US | disclosed |
| US-5627176-A | MIXED WITH CHOLESTEROL BIOSYNTHESIS INHIBITOR; PREVENTING ATHEROSCLEROSIS | SCHERING CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0751934-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026334-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1995-10-05 | — | — | WO | disclosed |